-
Something wrong with this record ?
Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin
M. Šíma, D. Bobek, P. Cihlářová, P. Ryšánek, J. Roušarová, J. Beroušek, M. Kuchař, T. Vymazal, O. Slanař
Language English Country Switzerland
Document type Journal Article
Grant support
Inter-Excellence (Action), under Grant LTAUSA-243018
Ministry of Education Youth and Sports
Cooperatio project (research area PHAR)
Charles University
SVV 260523
Charles University
A1_FPBT_2022_007
Specific University Research
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
The objective of this prospective study was to examine the exposure to the main active metabolites of ciprofloxacin in critically ill patients and to examine the factors (demographic, laboratory and genetic) that could potentially affect the drug metabolic conversion of ciprofloxacin. The secondary aim was to develop a population pharmacokinetic model for the metabolite showing the most associations with the abovementioned factors. A total of 29 patients were treated with intravenous infusion of ciprofloxacin and enrolled on this trial. Blood samples for pharmacokinetic analysis were taken at 1, 4, and 11.5 h following the completion of the infusion. Sex, age, body weight, height, serum creatinine and bilirubin levels, and creatinine clearance (CLCR) were recorded, and polymorphisms rs2032582 and rs1045642 in the ABCB1 gene, rs4148977 in the SLCO1A2 gene and rs762551 in the CYP1A2 gene were analyzed. A three-stage parent drug-metabolite population pharmacokinetic model was developed. Median (IQR) metabolite/parent ratios of the desethylene ciprofloxacin, formyl ciprofloxacin and oxociprofloxacin were 5.86 (4.09-9.87)%, 4.08 (3.38-6.92)% and 5.91 (3.42-13.65)%, respectively. The desethylene ciprofloxacin metabolic ratio was positively associated with height (r2 = 0.2277, p = 0.0089) and CLCR (r2 = 0.2023, p = 0.0144) and negatively associated with age (r2 = 0.2227, p = 0.0112). Males had a significantly higher oxociprofloxacin metabolic ratio than females (9.14 vs 3.42%, p = 0.0043). In the desethylene ciprofloxacin population PK model, the volume of distribution decreased with age, the parent drug-metabolite transfer rate constant increased with CLCR, and the metabolite elimination rate constant decreased with age and is increased in CYP1A2 rs762551 variant allele carriers. We therefore hypothesized that the CYP1A2 inhibition by ciprofloxacin is mediated by its metabolite desethylene ciprofloxacin.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22023591
- 003
- CZ-PrNML
- 005
- 20221031095246.0
- 007
- ta
- 008
- 221010s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics14081627 $2 doi
- 035 __
- $a (PubMed)36015253
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $1 000000026541738X
- 245 10
- $a Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin / $c M. Šíma, D. Bobek, P. Cihlářová, P. Ryšánek, J. Roušarová, J. Beroušek, M. Kuchař, T. Vymazal, O. Slanař
- 520 9_
- $a The objective of this prospective study was to examine the exposure to the main active metabolites of ciprofloxacin in critically ill patients and to examine the factors (demographic, laboratory and genetic) that could potentially affect the drug metabolic conversion of ciprofloxacin. The secondary aim was to develop a population pharmacokinetic model for the metabolite showing the most associations with the abovementioned factors. A total of 29 patients were treated with intravenous infusion of ciprofloxacin and enrolled on this trial. Blood samples for pharmacokinetic analysis were taken at 1, 4, and 11.5 h following the completion of the infusion. Sex, age, body weight, height, serum creatinine and bilirubin levels, and creatinine clearance (CLCR) were recorded, and polymorphisms rs2032582 and rs1045642 in the ABCB1 gene, rs4148977 in the SLCO1A2 gene and rs762551 in the CYP1A2 gene were analyzed. A three-stage parent drug-metabolite population pharmacokinetic model was developed. Median (IQR) metabolite/parent ratios of the desethylene ciprofloxacin, formyl ciprofloxacin and oxociprofloxacin were 5.86 (4.09-9.87)%, 4.08 (3.38-6.92)% and 5.91 (3.42-13.65)%, respectively. The desethylene ciprofloxacin metabolic ratio was positively associated with height (r2 = 0.2277, p = 0.0089) and CLCR (r2 = 0.2023, p = 0.0144) and negatively associated with age (r2 = 0.2227, p = 0.0112). Males had a significantly higher oxociprofloxacin metabolic ratio than females (9.14 vs 3.42%, p = 0.0043). In the desethylene ciprofloxacin population PK model, the volume of distribution decreased with age, the parent drug-metabolite transfer rate constant increased with CLCR, and the metabolite elimination rate constant decreased with age and is increased in CYP1A2 rs762551 variant allele carriers. We therefore hypothesized that the CYP1A2 inhibition by ciprofloxacin is mediated by its metabolite desethylene ciprofloxacin.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bobek, Daniel $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic
- 700 1_
- $a Cihlářová, Petra $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, 166 28 Prague, Czech Republic $1 0000000165520697
- 700 1_
- $a Ryšánek, Pavel $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $1 0000000167271663
- 700 1_
- $a Roušarová, Jaroslava $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic
- 700 1_
- $a Beroušek, Jan $u Department of Anesthesiology and ICM, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic
- 700 1_
- $a Kuchař, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, 166 28 Prague, Czech Republic $1 0000000276166352
- 700 1_
- $a Vymazal, Tomáš $u Department of Anesthesiology and ICM, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $1 0000000253577562
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 8 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36015253 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20221010 $b ABA008
- 991 __
- $a 20221031095243 $b ABA008
- 999 __
- $a ind $b bmc $g 1853930 $s 1174879
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 8 $e 20220804 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a Inter-Excellence (Action), under Grant LTAUSA-243018 $p Ministry of Education Youth and Sports
- GRA __
- $a Cooperatio project (research area PHAR) $p Charles University
- GRA __
- $a SVV 260523 $p Charles University
- GRA __
- $a A1_FPBT_2022_007 $p Specific University Research
- LZP __
- $a Pubmed-20221010